With
the popularity of computers and mobile phones, people are spending more
and more time to spend in the electrical equipment. However, for a long time watching the screen also allows the eye overwhelmed. In recent years, eye disease patient population size has been a growing trend. Therefore, more and more companies began to strengthen in the biomedical aspects of eye disease research, especially with the
age-related eye diseases.
Roche's Genentech recently announced that it would invest Ophthotech
company for the treatment of age-related macular degeneration (AMD) new
drug Pegpleranib, and will be another pharmaceutical giant Novartis
share this medicine overseas copyright.
Is sought after the two giants pegpleranib is currently in two Phase III clinical studies. Researchers are evaluated on the drug and Genentech's Lucentis combined with the effect. Pegpleranib is an anti-platelet-derived growth factor, can prevent blood vessels associated with AMD mistake growth. The Lucentis is a vascular endothelial growth factor inhibitor drugs. Ophthotech company believes this two drugs can play a good synergy in AMD treatment. Two clinical studies expected to be completed in the fourth quarter of 2017. In addition, the company will phase III clinical study with Roche's
Avastin Eylea pegpleranib and regeneration of dollars and will be
combined with.
As early as in 2014, Novartis and Ophthotech company seeking to develop the drug reached a cooperation agreement. Novartis to Ophthotech company paid $ 200 million in advances and milestones of up to $ 800 million in prize money. On the other hand, Novartis added for Genentech surely welcomed. Since
early in 2003, Novartis gained the right to sell Lucentis outside the
US from Genentech aspect, so this will also join the Genentech makes
tripartite more smoothly in the drug development.
( Bolise Co., Ltd. www.chemicalspharm.com )
没有评论:
发表评论